Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. By Zhao et al. 2014 

Sexual Bother in Men with Advanced Prostate Cancer Undergoing Androgen Deprivation Therapy. By Benedict et al. 2014 

Positive and negative mood in men with advanced prostate cancer undergoing androgen deprivation therapy: considering the role of social support and stress. By Benedict et al. 2014 

Risk of New-onset Diabetes after Androgen Deprivation Therapy for Prostate Cancer in the Asian Population. By Teoh et al. 2014 

Muscle and bone effects of androgen deprivation therapy: current and emerging therapies. By Lee et al. 2014 

Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment. By Graham-Steed et al. 2014.

Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study. By Morgans et al. 2014.

Androgen-deprivation-associated bone disease. By Skolarus et al. 2014.

Adverse effects of androgen deprivation therapy in prostate cancer and their management. By Rhee et al. 2014

Quality of life improvement for patients treated with degarelix versus leuprorelin in advanced prostate cancer. By Lee et al. 2014

Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer.

Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. By Parekh et al. 2014 

Trans-Pacific variation in outcomes for men treated with primary androgen deprivation therapy for prostate cancer. By Cooperberg et al. 2014